Sponsor Directory

Janssen Research & Development, LLC clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

703

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Down Syndrome, Alzheimer's Disease
Interventions: Not listed
Lead sponsor: Michael Rafii; Other
Eligibility: 30 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Healthy
Interventions: Odalasvir 100 mg, Placebo, Odalasvir 500 mg, Odalasvir (Up to maximum 1000 mg); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Atrial Fibrillation
Interventions: Rivaroxaban (Xarelto, BAY59-7939), VKA (Vitamin K antagonist); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 38,831 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Aripiprazole, Olanzapine, Paliperidone, Quetiapine, Risperidone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Torrance, California • Kissimmee, Florida • Conshohocken, Pennsylvania

Conditions: Healthy
Interventions: Ibrutinib, IMBRUVICA; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Alzheimer's Disease
Interventions: AAB-003 (PF-05236812); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 15
States / cities: Hallandale, Florida • Ocala, Florida • Atlanta, Georgia + 7 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin 100 mg, Canagliflozin 50 mg, Canagliflozin 300 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 13
States / cities: Little Rock, Arkansas • Los Angeles, California • Aurora, Colorado + 10 more

Conditions: Hepatitis C Virus
Interventions: Simeprevir 150 mg, Daclatasvir 60 mg, Sofosbuvir 400 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 7
States / cities: Bakersfield, California • Jacksonville, Florida • Lutherville, Maryland + 4 more

Conditions: Chronic Lymphocytic Leukemia With 17p Deletion, Small Lymphocytic Lymphoma With 17p Deletion
Interventions: Ibrutinib; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 18
States / cities: Phoenix, Arizona • Duarte, California • Greenbrae, California + 15 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin, Placebo, Sitagliptin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 678 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 24
States / cities: Phoenix, Arizona • Concord, California • Greenbrae, California + 21 more

Conditions: Hepatitis C Virus
Interventions: Daclatasvir, Simeprevir, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: San Francisco, California • Indianapolis, Indiana • Lutherville, Maryland + 3 more

Conditions: Alzheimer's Disease
Interventions: AAB-003 (PF-05236812), Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 23
States / cities: Escondido, California • Hallandale, Florida • Ocala, Florida + 11 more

About this Janssen Research & Development, LLC sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where Janssen Research & Development, LLC is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Janssen Research & Development, LLC trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Janssen Research & Development, LLC clinical trials

Filter and sort this sponsor

Live official records

Down Syndrome Biomarker Initiative (DSBI)

A Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of Odalasvir Administered as a Single Dose Tablet Under Fed Conditions in Healthy Participants

Real-world Comparative Effectiveness of Rivaroxaban Versus VKA

A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus

Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection

A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

About this Janssen Research & Development, LLC sponsor directory page